Drug-Eluting Stents Market to Reach USD 14.2 Billion by 2035 from USD 7.7 Billion in 2024, Expanding at 5.7% CAGR

The global drug-eluting stents market was valued at US$ 7.7 Bn in 2024 and is projected to grow at a CAGR of 5.7% from 2025 to 2035, reaching more than US$ 14.2 Bn by the end of 2035. Growth in the market is being supported by technological advancements in stent design and drug delivery, the rising prevalence of cardiovascular diseases, growing awareness regarding cardiovascular health, and increasing demand for minimally invasive interventions.

Drug-eluting stents (DES) have become an important component of interventional cardiology because they release therapeutic drugs directly at the site of arterial treatment. This helps prevent excessive tissue growth and reduces the risk of restenosis following angioplasty. Continued development of advanced polymers, drug combinations, and stent platforms is further contributing to the evolution of DES technology.

→Discover Market Opportunities - Request Your Sample Copy Now: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=30632

Analysts’ Viewpoint

The global drug-eluting stents market has experienced healthy growth in recent years, supported by technological developments and the increasing prevalence of cardiovascular diseases. Drug-eluting stents are designed to deliver medication locally to prevent artery blockage following angioplasty and provide improved outcomes compared with traditional bare-metal stents.

The market is benefiting from the increasing demand for less-invasive treatment approaches, an aging population, and greater awareness of cardiovascular diseases. Technological developments involving newer drugs and advanced stent materials are improving biocompatibility and device performance, while the increasing incidence of cardiovascular disease, particularly in developing nations, is contributing to demand.

Government programs and reimbursement policies supporting cardiovascular treatment are also helping expand access to interventional procedures. At the same time, the growing adoption of minimally invasive interventions and interventional cardiology is creating additional opportunities for drug-eluting stent manufacturers.

However, the high cost associated with drug-eluting stents and potential complications such as restenosis and thrombosis may restrain market expansion. Ongoing research and development activities focused on improving stent safety, drug delivery, polymers, and device platforms are expected to address these challenges and support long-term market development.

Market Introduction

Drug-eluting stents are sophisticated medical devices used primarily in the treatment of coronary artery disease. These stents generally consist of a metal mesh platform coated with medication that is gradually released after implantation. The drug helps suppress excessive tissue growth inside the artery, thereby reducing the possibility of restenosis after angioplasty.

Compared with bare-metal stents, drug-eluting stents have contributed to improved patient outcomes and reduced the likelihood of repeat revascularization procedures. Technological progress has further improved their performance through developments in polymers, drug-delivery mechanisms, and stent materials.

The adoption of DES has increased with growing cardiovascular awareness and the rising incidence of heart disease, particularly among aging populations. Innovations in novel polymers and drug-delivery technologies are also improving the safety, performance, and biocompatibility of these devices, supporting their use across developed and emerging healthcare markets.

Nevertheless, challenges remain, including high treatment costs and potential long-term complications such as stent thrombosis. Continued research into second-generation drug-eluting stents, advanced drug combinations, and improved device platforms is expected to address these limitations. As cardiovascular disease continues to create a substantial healthcare burden worldwide, demand for effective and minimally invasive treatment technologies is expected to remain strong.

Introduction of Advanced Drug-Eluting Stents to Drive Market Growth

The introduction of advanced drug-eluting stents is a major factor supporting the expansion of the global market. New-generation DES technologies are increasingly designed to improve patient outcomes by delivering therapeutic drugs directly to the arterial wall and reducing the possibility of restenosis following vascular intervention.

Advances in drug delivery, polymer science, and stent technology have improved device biocompatibility and therapeutic efficacy. These developments are particularly significant as healthcare providers seek minimally invasive approaches for treating coronary artery disease and other vascular conditions.

Next-generation drug-eluting stents can also reduce the need for repeat procedures, which is an important consideration for both patients and healthcare systems. Continued research and development is leading to stents incorporating biodegradable platforms and sophisticated drug-delivery systems, creating opportunities for further innovation.

The development of advanced DES technology is therefore contributing to a broader evolution in cardiovascular intervention. As healthcare professionals increasingly adopt newer technologies, improvements in patient care and the potential reduction of long-term healthcare costs are expected to support market growth.

Rising Prevalence of Cardiovascular Disease to Boost Drug-Eluting Stents Market Expansion

The increasing prevalence of cardiovascular diseases worldwide is another significant factor driving the drug-eluting stents market. Cardiovascular diseases, including coronary artery disease, heart attack, and stroke, represent major causes of death and disability. Factors associated with the increasing burden include population aging, physical inactivity, unhealthy dietary patterns, diabetes, and hypertension.

As the number of patients requiring cardiovascular treatment increases, demand for effective interventional procedures is also expected to rise. Drug-eluting stents provide a therapeutic approach for patients undergoing percutaneous coronary intervention by releasing drugs that suppress cellular growth and help reduce narrowing of the artery following treatment.

Growing awareness of cardiovascular risk factors and the benefits of early intervention is contributing to greater adoption of DES in clinical practice. Healthcare systems are increasingly focused on managing the cardiovascular disease burden through less-invasive therapies that can improve patient outcomes and potentially reduce the need for repeated cardiovascular interventions.

The combination of rising cardiovascular disease prevalence, an aging population, and advances in interventional cardiology is therefore expected to remain an important contributor to the expansion of the drug-eluting stents market through the forecast period.

→Explore Strategies & Trends - Request Full Report Access – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=30632

Polymer Material Segment Leads the Global Drug-Eluting Stents Market

The polymer material segment accounted for the leading position in the global drug-eluting stents market. Polymers are important components of DES technology because they can function as carriers for therapeutic agents and help regulate the release of drugs at the treatment site.

Controlled drug release allows therapeutic agents to be delivered locally to the arterial wall over a specific period. This mechanism helps reduce the risk of restenosis while supporting the effectiveness of the intervention.

Advances in polymer technology have resulted in the development of biocompatible and biodegradable materials aimed at improving patient outcomes and addressing complications associated with permanent implantation. Biodegradable polymers gradually degrade within the body and can potentially reduce concerns associated with permanent polymer coatings.

Polymer materials also provide flexibility and adaptability in stent design. Their characteristics can support the development of devices capable of navigating complex vascular geometries, which is important for a broad range of clinical applications.

As demand increases for advanced and patient-specific cardiovascular interventions, innovation in polymer materials is expected to remain an important area of development in the drug-eluting stents market.

Drug-Eluting Stents Market: Regional Outlook

North America held the largest share of the global drug-eluting stents market in 2024. The region's leading position is supported by technological innovation, a developed healthcare infrastructure, increasing cardiovascular disease prevalence, and a growing aging population.

North America has a highly developed healthcare system that enables broad access to advanced medical technologies, including drug-eluting stents. The increasing demand for efficient cardiovascular treatment solutions has further supported the adoption of DES across the region.

Significant research and development investments by medical device companies operating in North America are contributing to innovation in stent design and drug-delivery technologies. These developments are focused on improving device effectiveness, safety, and biocompatibility, supporting wider adoption among physicians and patients.

The region's regulatory environment also plays an important role in bringing advanced medical products to the market. Established healthcare facilities and high levels of health insurance coverage further support access to advanced cardiovascular interventions.

As patients and clinicians increasingly seek minimally invasive procedures with improved outcomes, demand for drug-eluting stents is expected to remain significant across North America.

Competitive Landscape of the Drug-Eluting Stents Market

The global drug-eluting stents market features several established medical device companies competing through product development, technological innovation, strategic business initiatives, and expansion of product portfolios. Key players operating in the market include Abbott Laboratories, AlviMedica, B. Braun Melsungen AG, Biosensors International Group, Ltd., Shandong JW Medical Systems LTD., Boston Scientific Corporation, Cook Medical Inc., Elixir Medical Corp., Lepu Medical Technology (Beijing) Co., Ltd., Medtronic plc, Eurocor GmbH, OrbusNeich Medical Company Limited, Shanghai MicroPort Medical Co., Ltd., and Sino Medical Sciences Technology Inc.

Companies operating in the market are profiled based on company overview, financial overview, business strategies, product portfolio, business segments, sales footprint, subsidiaries or distributors, and recent developments. Competition is also influenced by ongoing advances in stent platforms, polymer materials, drug-delivery technologies, and cardiovascular intervention solutions.

Key Developments in the Drug-Eluting Stents Market

In June 2024, Elixir Medical's DynamX Sirolimus-Eluting Coronary Bioadaptor System received Breakthrough Device Designation from the U.S. FDA. The bioadaptive implant is designed to improve coronary luminal diameter, restore hemodynamic modulation, and reduce plaque progression in patients with symptomatic ischemic heart disease.

In May 2024, Abbott announced the launch of the XIENCE Sierra Everolimus drug-eluting coronary stent system in India. The system is CE-marked and represents one of the latest-generation stents in the XIENCE family.

These developments highlight the continued emphasis on advanced stent platforms and drug-delivery technologies aimed at improving cardiovascular intervention outcomes.

Drug-Eluting Stents Market Segmentation

The drug-eluting stents market is segmented based on material, drug, application, and end-user. By material, the market is divided into metal and polymer. Metal is further classified into stainless steel, cobalt-chromium, nitinol, and others, while polymer includes non-biodegradable polymers and biodegradable polymers.

Based on drug, the market is segmented into sirolimus, paclitaxel, zotarolimus, everolimus, and others. By application, the market covers coronary artery disease, peripheral artery disease, and others. Based on end-user, the market is divided into hospitals, ambulatory surgical centers, and others.

Geographically, the market covers North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Countries analyzed include the U.S., Canada, Germany, the U.K., France, Italy, Spain, China, Australia & New Zealand, India, Japan, Brazil, Mexico, GCC countries, and South Africa.

Drug-Eluting Stents Market Snapshot

The global drug-eluting stents market was valued at US$ 7.7 Bn in 2024 and is projected to reach US$ 14.2 Bn by 2035, expanding at a CAGR of 5.7% during 2025–2035. Historical data is available for 2020–2024, while the forecast period covers 2025–2035.

The market analysis includes segment-level and regional analysis, along with qualitative assessment of market drivers, restraints, opportunities, key trends, value chain analysis, and competitive developments. The competition landscape includes a competition matrix and detailed company profiles covering company overview, product portfolio, sales footprint, key subsidiaries or distributors, strategies, recent developments, and key financial information.

The report is available in electronic PDF and Excel formats and provides a comprehensive assessment of the evolving global drug-eluting stents industry.

Buy Full Report Now: https://www.transparencymarketresearch.com/checkout.php?rep_id=30632<ype=S

→Explore Latest Research Reports by Transparency Market Research:

Microcatheter Market

Platelet Incubator Market

Sanitization Robots Market

Kidney Dialysis Equipment Market

Infant Resuscitators Market

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com 

Sales Inquiries: sales@transparencymarketresearch.com

Media Inquiries: media@transparencymarketresearch.com